On Saturday, February 20th, I attended the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE)’s Consensus Meeting on Continuous Glucose Monitoring in Washington, D.C. As I posted late last week, I was invited to participate in this important discussion on behalf of the patient community, with Henry Anhalt, D.O., Chief Medical Officer at T1D Exchange on the panel of physicians advocating for the expanded use of CGMs by diabetes patients.
The meeting brought together a diverse group of diabetes care thought leaders, including scientific and medical societies, patient advocacy groups, government, insurance, and pharmaceutical and medical device manufacturers. These different groups met individually in the morning session to discuss and respond to four key questions asked by AACE/ACE.
These questions were:
- How would patients, practitioners and payers benefit from expanded use of personal and professional CGM?
- What CGM data is relevant and how should it be reported?
- How should the data and reporting be interpreted?
- What clinical data is currently available to support expanded CGM coverage by payers as pertains to Questions 1-and 3? What additional data is needed?
I presented data and anecdotal evidence on patient CGM use and value from Glu to other representatives from the patient community, including JDRF, Children With Diabetes, Diabetes Patient Advocacy Coalition, and the National Diabetes Volunteer Leadership Council. Several Questions of the Day helped shape our discussion throughout the morning.
Later, the opinions of the smaller groups, or “pillars,” were represented by members of AACE/ACE during a panel discussion, which all participants were invited to attend.
Dr. Bruce Buckingham, Professor of Pediatric Endocrinology at Stanford University School of Medicine, cited T1D Exchange data on CGM use, hypoglycemia and HbA1c levels during his opening address. Various speakers on the AACE/ACE panel also mentioned T1D Exchange studies throughout the day, showing the value of Glu and patient-driven research to these diabetes thought leaders.
At the end of the meeting, AACE/ACE wrote and released a conclusion statement on expanded CGM use, which included the following key outcomes:
- There is robust data which supports benefits of CGM use in many people with diabetes, particularly those with type 1 diabetes
- Technological advances have improved CGM reliability and accuracy
- CGM use has reduced hypoglycemia while improving blood glucose control, ensuring patient safety
- There is data that suggests CGMs may benefit other patient populations, such as patients with type 2 diabetes on intensive insulin therapy
- Studies are needed to demonstrate the value of CGM technology in other patient populations
- Access should be expanded to all patient populations with proven benefits
At Glu, our mission is to drive research using the patient voice. Participating in this important meeting and bringing that voice to the conversation around CGM use is a prime example of how being engaged really can make a difference to patients and families like yours and mine. It was a great day for Glu!
-Amy Bevan, GluMom